

Sub B2/ 19. (New) The medical device according to <sup>any</sup> one of claims 15, 16, 17, or 18 wherein said three-dimensional matrix comprises multiple layers of nitric oxide-releasing nucleophiles entrapped within said three dimensional matrix.

20. (New) A method for treating or preventing restenosis comprising: providing a medical devices having a polymer coating comprising a compound having combined cytostatic, antithrombogenic, vasodilatory and antiproliferative effects; and delivering said medical device to the treatment such that said compound is released from said medical device in a controlled fashion.

21. (New) The method according to claim 19 wherein said compound is a nitric-oxide releasing nucleophile. 13

Sub B3/ 22. (New) The method according to claim 19 wherein said medical device is selected from the group consisting of stents, grafts, guide wires, and catheters.

23. (New) A method for providing a metallic medical device with a surface having multi-functional molecules comprising:

applying an amine-fuctionalized silane to a metallic surface for a time sufficient, and under conditions suitable for said amine-fuctionalized silane to bind to said metallic surface.

24. (New) The method according to claim 23 wherein said amine-fuctionalized silane is selected from the group consisting of 4,7,10-triazadecyl-trimethoxysilane, 3-aminopropyltriethoxysilane, trichloro<sup>13</sup>propylsilane, 3-aminopropyltrimethoxysilane, 3-aminopropyldiisopropylethoxysilane, and 3-aminopropylmethyldiethoxysilane.

Sub B4/ 25. (New) A method for providing a metallic medical device with a surface having multi-functional molecules comprising:

applying a reactive isocyanatosilane to a metallic surface for a time sufficient, and under conditions suitable for said amine-fuctionalized silane to bind to said metallic surface; and

coupling a nucleophile to said reactive isocyanatosilane.

26. (New) The method according to claim 25 wherein said isocyanatosilane is 3-isocyanatopropyltriethoxysilane. 8

10  
27. (New) The method according to claim ~~26~~<sup>9</sup> wherein said nucleophile is selected from the group consisting of C<sub>1</sub>-C<sub>10</sub> cycloalkyl, alkyl and alkenyl monoamines, methylamine, ethylamin , diethylamin , ethylmethylamine, triethylamine, n-propylamine, allylamine, isopropylamine, n-butylamine, n-butylmethylamine, n-amylamine, n-hexylamine, 2-ethylhexylamine, cyclohexylamine, ethylenediamine, polyethyleneamine, 1,4-butanediamine, 1,6-hexanediamine, n-methylcyclohexylamine, alkeneamines, ethyleneimine and polyethylenimine.

11 28. (New) A method according to claims ~~23~~<sup>7</sup> or ~~26~~<sup>8</sup> wherein in said medical device is selected from the group consisting of stents, grafts, guide wires, and catheters.

Sub (B5)  
29. (New) A method for providing a metallic medical device with a polyethylenimine (PEI) coating comprising:

cleaning said metallic medical device;  
applying an amine-functionalized silane to said cleaned metallic medical device to form a silanized metallic medical device;  
forming a hydrogel coating on said silanized metallic medical device to form a hydrogel coated metallic medical device;  
grafting PEI to said hydrogel coated metallic medical device to form a PEI coated metallic medical device.

113 30. (New) The method according to claim ~~29~~<sup>12</sup> further comprising:  
crosslinking said PEI on said PEI coated medical device to form a crosslinked PEI coating.

14 31. (New) The method according to claim ~~30~~<sup>13</sup> further comprising:  
providing said crosslinked PEI coating with nucleophile residues.

Sub (B5)  
32. (New) A medical device having a PEI coating according to any one of claims 29, 30, or 31.

In view of the above remarks and amendments, it is submitted that pending claims ~~6-36~~<sup>15-32</sup>, are in condition for allowance and their allowance is earnestly solicited.

No additional fees are seen as being necessary in connection for this amendment. However, th Examiner is authorized to charge any additional fees or credit any overpayment to Deposit Account 50-1901.

If any issues remain, the Examiner is urged to contact the undersigned by telephone for a prompt resolution thereof.

Respectfully submitted,



Louis C. Cullman  
Registration No. 39, 645

March 6, 2002

OPPENHEIMER WOLFF & DONNELLY LLP  
840 Newport Center Drive, Suite 700  
Newport Beach, CA 92660  
Telephone: 949.823.6000  
Facsimile: 949.823.6100